Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report

Marco Scarati, Simone Parisi, Richard Borrelli, Maria Bruzzone, Marta Priora, Clara Lisa Peroni, Enrico Fusaro

DOI: https://doi.org/10.7175/cmi.v11i1.1286

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by multisystemic involvement. Owing to multifactorial etiologies, low bone mineral density (BMD) osteoporosis (OP) and fragility fractures (FFx) have been very frequently documented in these patients. Appropriate treatments to minimize underlying immunologic disease activity remain mandatory, and the development of strategies to prevent and treat important complications as osteoporosis is needed.

We present the clinical case of a female SLE patient treated simultaneously with belimumab (anti-BLyS) for the underlying disease, and denosumab (anti-RANKL) for concomitant severe osteoporosis. As these monoclonal antibodies have been recently introduced into the market, their combination has not been reported in literature yet. In this case, the combined administration proved a viable option for a SLE patient with osteoporosis and bisphosphonates contraindications.

Keywords

Systemic Lupus Erythematosus; Belimumab; Denosumab

Full Text:

HTML PDF

References

  • Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39; https://doi.org/10.1056/NEJMra071297
  • Vilas-Boas A, Morais SA, Isenberg DA. Belimumab in systemic lupus erythematosus. RMD Open 2015; 1: e000011; https://doi.org/10.1136/rmdopen-2014-000011
  • Larosa M, Iaccarino L, Gatto M, et al. Advances in the diagnosis and classification of systemic lupus erythematosus. Expert Rev Clin Immunol 2016; 12: 1309-20 https://doi.org/10.1080/1744666x.2016.1206470
  • Kuhn A, Bonsmann G, Anders HJ, et al. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 2015; 112: 423-32; https://doi.org/10.3238/arztebl.2015.0423
  • Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum 2012; 64: 2677-86; https://doi.org/10.1002/art.34473
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725; https://doi.org/10.1002/art.1780400928
  • Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014; 48-9: 10-3; https://doi.org/10.1016/j.jaut.2014.01.004
  • Yee CS, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 111-3; https://doi.org/10.1136/ard.2003.018127
  • Bultink IE, Lems WF. Systemic lupus erythematosus and fractures. RMD Open 2015; 1(Suppl 1): e000069; https://doi.org/10.1136/rmdopen-2015-000069
  • Rentero ML, Amigo E, Chozas N, et al; GHDP study group. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. BMC Musculoskelet Disord 2015; 16: 300; https://doi.org/10.1186/s12891-015-0733-9
  • Cramarossa G, Urowitz MB, Su J, et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus 2016 Aug 13 [Epub ahead of print]; https://doi.org/10.1177/0961203316664597
  • Carli L, Tani C, Spera V, et al. Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med 2016; 3: e000098; https://doi.org/10.1136/lupus-2015-000098
  • Salman-Monte TC, Torrente-Segarra V, Muñoz-Ortego J, et al. Prevalence and predictors of low bone density and fragility fractures in women with systemic lupus erythematosus in a Mediterranean region. J Rheumatol Int 2015; 35: 509-15; https://doi.org/10.1007/s00296-014-3087-y
  • Bultink IEM. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 2012; 64: 2-8; https://doi.org/10.1002/acr.20568
  • Di Munno O, Mazzantini M, Delle Sedie A, et al. Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus 2004; 3: 724-30; https://doi.org/10.1191/0961203303lu1097oa
  • Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10: 365-73; https://doi.org/10.1038/nrrheum.2014.33
  • Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 2016; 3: e000118; https://doi.org/10.1136/lupus-2015-000118
  • Hanley DA, Adachi JD, Bell A, et al. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012; 66: 1139-46; https://doi.org/10.1111/ijcp.12022
  • Suresh E, Abrahamsen B. Denosumab: a novel antiresorptive drug for osteoporosis. Cleve Clin J Med 2015; 82: 105-14; https://doi.org/10.3949/ccjm.82a.13173
  • Törring O. Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis 2015; 7: 88-102; https://doi.org/10.1177/1759720X15579189

Refbacks

  • There are currently no refbacks.




© SEEd srl